Answers are grounded in this paper and cite their sources.
The fluoride-containing bioactive glass F3 with nominal composition (mol%) 44.8 SiO2 - 2.5 P2O3 - 36.5 CaO - 6.6 Na2O - 6.6 K2O - 3.0 CaF2 is a highly promising candidate for bone replacement applications. Its strong crystallization tendency, however, requires a thorough understanding of the interplay between glass powder particle size, surface crystallization, and sintering. Therefore, this study characterizes the sintering and crystallization of bulk specimens and various particle size fractions by differential thermal-analysis, laser scanning, electron microscopy, X-ray diffraction, and Infrared spectroscopy. Particle size fractions < 56 µm were found to fully densify, while crystals growing from the glass particle surface retard sintering of coarser fractions. Small amounts of a non-stoichiometrically calcium phosphosilicate (Ca14.92(PO4)2.35(SiO4)5.65) occurs as the primary crystal phase followed by combeite (Na4Ca4[Si6O18]) as a temporarily dominating phase. The surface crystallization of both phases was found to be mainly responsible for sinter retardation. During later stages of crystallization, additional phases such as cuspidine (Ca4F2Si2O7) and silicorhenanite (Na2Ca4(PO4)2SiO4) occur, but finally monoclinic wollastonite (CaSiO3) forms as the dominant phase.
No takes yet. Share an insight, caveat, or question.
Blaeß et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: